Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.

Saha D, Rabkin SD.

Methods Mol Biol. 2020;2058:179-190. doi: 10.1007/978-1-4939-9794-7_11.

PMID:
31486038
2.

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.

Nigim F, Kiyokawa J, Gurtner A, Kawamura Y, Hua L, Kasper EM, Brastianos PK, Cahill DP, Rabkin SD, Martuza RL, Carbonell WS, Wakimoto H.

Target Oncol. 2019 Aug;14(4):479-489. doi: 10.1007/s11523-019-00654-4.

PMID:
31301014
3.

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.

Ning JF, Stanciu M, Humphrey MR, Gorham J, Wakimoto H, Nishihara R, Lees J, Zou L, Martuza RL, Wakimoto H, Rabkin SD.

Nat Commun. 2019 Jul 2;10(1):2910. doi: 10.1038/s41467-019-10993-5.

4.

A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS).

Wu MR, Nissim L, Stupp D, Pery E, Binder-Nissim A, Weisinger K, Enghuus C, Palacios SR, Humphrey M, Zhang Z, Maria Novoa E, Kellis M, Weiss R, Rabkin SD, Tabach Y, Lu TK.

Nat Commun. 2019 Jun 28;10(1):2880. doi: 10.1038/s41467-019-10912-8.

5.

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.

Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL.

Oncoimmunology. 2019 Apr 7;8(7):1591875. doi: 10.1080/2162402X.2019.1591875. eCollection 2019.

6.
7.

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.

Wang L, Ning J, Wakimoto H, Wu S, Wu CL, Humphrey MR, Rabkin SD, Martuza RL.

Mol Ther Oncolytics. 2019 Mar 29;13:58-66. doi: 10.1016/j.omto.2019.03.008. eCollection 2019 Jun 28.

8.

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade.

Bommareddy PK, Rabkin SD, Kaufman HL.

Oncoimmunology. 2019 Feb 3;8(4):e1571390. doi: 10.1080/2162402X.2019.1571390. eCollection 2019.

9.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.

Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H.

Sci Rep. 2019 Jan 15;9(1):139. doi: 10.1038/s41598-018-37437-2.

10.

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.

Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL.

Sci Transl Med. 2018 Dec 12;10(471). pii: eaau0417. doi: 10.1126/scitranslmed.aau0417.

PMID:
30541787
11.

Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.

Saha D, Martuza RL, Rabkin SD.

Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.

12.

Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Peters C, Paget M, Tshilenge KT, Saha D, Antoszczyk S, Baars A, Frost T, Martuza RL, Wakimoto H, Rabkin SD.

J Virol. 2018 Jul 17;92(15). pii: e00246-18. doi: 10.1128/JVI.00246-18. Print 2018 Aug 1.

13.

Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL.

Clin Cancer Res. 2018 Jul 15;24(14):3409-3422. doi: 10.1158/1078-0432.CCR-17-1717. Epub 2018 Mar 29.

14.

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.

Saha D, Martuza RL, Rabkin SD.

Oncoscience. 2017 Sep 20;4(7-8):67-69. doi: 10.18632/oncoscience.359. eCollection 2017 Jul. No abstract available.

15.

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Saha D, Martuza RL, Rabkin SD.

Cancer Cell. 2017 Aug 14;32(2):253-267.e5. doi: 10.1016/j.ccell.2017.07.006.

16.

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W Jr, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.

Int J Cancer. 2017 Dec 1;141(11):2348-2358. doi: 10.1002/ijc.30929. Epub 2017 Aug 26.

17.

Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.

Ning J, Wakimoto H, Peters C, Martuza RL, Rabkin SD.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-13. doi: 10.1093/jnci/djw229.

18.

Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.

Antoszczyk S, Rabkin SD.

Expert Opin Orphan Drugs. 2016;4(2):129-138. Epub 2015 Dec 26.

19.

Oncolytic herpes simplex virus interactions with the host immune system.

Saha D, Wakimoto H, Rabkin SD.

Curr Opin Virol. 2016 Dec;21:26-34. doi: 10.1016/j.coviro.2016.07.007. Epub 2016 Aug 3. Review.

20.

Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.

Esaki S, Rabkin SD, Martuza RL, Wakimoto H.

Am J Cancer Res. 2016 Jan 15;6(2):300-11. eCollection 2016.

21.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H.

Neuro Oncol. 2016 Sep;18(9):1278-87. doi: 10.1093/neuonc/now031. Epub 2016 Mar 6.

22.

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Saha D, Ahmed SS, Rabkin SD.

Drugs Future. 2015;40(11):739-749.

23.

Designing Herpes Viruses as Oncolytics.

Peters C, Rabkin SD.

Mol Ther Oncolytics. 2015;2. pii: 15010. Epub 2015 Jul 22.

24.

Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.

Nigim F, Cavanaugh J, Patel AP, Curry WT Jr, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H.

J Neuropathol Exp Neurol. 2015 Jul;74(7):710-22. doi: 10.1097/NEN.0000000000000210.

25.

Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.

Wang JN, Xu LH, Zeng WG, Hu P, Rabkin SD, Liu RR.

Asian Pac J Cancer Prev. 2015;16(3):1241-5.

26.

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.

Wang J, Xu L, Zeng W, Hu P, Zeng M, Rabkin SD, Liu R.

Cancer Cell Int. 2014 Sep 19;14(1):83. doi: 10.1186/s12935-014-0083-y. eCollection 2014.

27.

Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.

Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H.

J Neurooncol. 2015 Jan;121(1):91-100. doi: 10.1007/s11060-014-1612-1. Epub 2014 Sep 12.

28.

Oncolytic viruses and their application to cancer immunotherapy.

Chiocca EA, Rabkin SD.

Cancer Immunol Res. 2014 Apr;2(4):295-300. doi: 10.1158/2326-6066.CIR-14-0015. Review. Erratum in: Cancer Immunol Res. 2014 Jul;2(7):699.

29.

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE.

Cell. 2014 Apr 24;157(3):580-94. doi: 10.1016/j.cell.2014.02.030. Epub 2014 Apr 10.

30.

Immunovirotherapy for the treatment of glioblastoma.

Cheema TA, Fecci PE, Ning J, Rabkin SD.

Oncoimmunology. 2014 Jan 1;3(1):e27218.

31.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

32.

Immunovirotherapy for glioblastoma.

Ning J, Wakimoto H, Rabkin SD.

Cell Cycle. 2014;13(2):175-6. doi: 10.4161/cc.27039. Epub 2013 Nov 14. No abstract available.

33.

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.

Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11. doi: 10.1073/pnas.1307935110. Epub 2013 Jun 10.

34.

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.

Neoplasia. 2013 Jun;15(6):591-9.

35.

An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE.

Cell Rep. 2013 May 30;3(5):1567-79. doi: 10.1016/j.celrep.2013.04.021. Epub 2013 May 23.

36.
37.

Current status of gene therapy for brain tumors.

Murphy AM, Rabkin SD.

Transl Res. 2013 Apr;161(4):339-54. doi: 10.1016/j.trsl.2012.11.003. Epub 2012 Dec 11.

38.

Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.

Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.

Stem Cells Transl Med. 2012 Apr;1(4):322-32. doi: 10.5966/sctm.2011-0035. Epub 2012 Mar 21.

39.

Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.

Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2013 Jan;20(1):17-24. doi: 10.1038/cgt.2012.75. Epub 2012 Nov 9.

40.

Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.

Mol Ther. 2013 Jan;21(1):68-77. doi: 10.1038/mt.2012.175. Epub 2012 Aug 28.

41.

Treatment of breast cancer stem cells with oncolytic herpes simplex virus.

Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin SD, Liu R.

Cancer Gene Ther. 2012 Oct;19(10):707-14. doi: 10.1038/cgt.2012.49. Epub 2012 Aug 17.

42.

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT Jr.

Neurosurgery. 2012 Sep;71(3):741-8; discussion 748. doi: 10.1227/NEU.0b013e318260fd73.

43.

Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Kanai R, Zaupa C, Sgubin D, Antoszczyk SJ, Martuza RL, Wakimoto H, Rabkin SD.

J Virol. 2012 Apr;86(8):4420-31. doi: 10.1128/JVI.00017-12. Epub 2012 Feb 15.

44.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509. Epub 2011 Dec 15.

45.

Oncolytic herpes simplex virus treatment of metastatic breast cancer.

Wang J, Hu P, Zeng M, Rabkin SD, Liu R.

Int J Oncol. 2012 Mar;40(3):757-63. doi: 10.3892/ijo.2011.1266. Epub 2011 Nov 21.

PMID:
22108767
46.

Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.

Wakimoto H, Mohapatra G, Kanai R, Curry WT Jr, Yip S, Nitta M, Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis DN, Martuza RL, Rabkin SD.

Neuro Oncol. 2012 Feb;14(2):132-44. doi: 10.1093/neuonc/nor195. Epub 2011 Nov 7.

47.

Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, Martuza RL.

Clin Cancer Res. 2011 Dec 1;17(23):7383-93. doi: 10.1158/1078-0432.CCR-11-1762. Epub 2011 Oct 5.

48.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

49.

Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.

Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner VF, Rabkin SD, Demestre M.

PLoS One. 2011;6(6):e21099. doi: 10.1371/journal.pone.0021099. Epub 2011 Jun 13.

50.

Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.

Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G.

Clin Cancer Res. 2011 Jul 1;17(13):4484-93. doi: 10.1158/1078-0432.CCR-11-0575. Epub 2011 May 10.

Supplemental Content

Loading ...
Support Center